• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服抗凝剂引发的动脉粥样硬化栓塞

Atheromatous embolization precipitated by oral anticoagulants.

作者信息

Bols A, Nevelsteen A, Verhaeghe R

机构信息

Department of Bleeding and Vascular Disorders, University Hospital Gasthuisberg, Leuven, Belgium.

出版信息

Int Angiol. 1994 Sep;13(3):271-4.

PMID:7822905
Abstract

Five patients with a "blue or purple" toe syndrome due to atheromatous embolization probably precipitated by oral anticoagulant therapy are reported. In four, the symptoms started a few weeks after initiation of oral anticoagulants and in the fifth they were clearly aggravated by coumarinic drugs. Prior to anticoagulation, one patient had received a course of thrombolytic therapy and two had undergone an arterial catherization without embolic events. A diagnostic arteriography performed in four patients caused no new symptoms. All patients had advanced atherosclerosis. A shaggy aorta and/or pelvic arteries were found in four and in the fifth a highly stenotic femoral lesion appeared the source of peripheral embolization. Oral anticoagulants were interrupted in all five and four underwent reconstructive vascular surgery to eradicate the nidus of atheromatous emboli. One died postoperatively from multiple organ failure. The poor condition of the fifth patient precluded aorto-iliac surgery. No new episodes of embolization occurred and the symptoms disappeared, although one patient needed a toe amputation for a skin lesion that had proceeded to gangrene. The possible role of anticoagulant drugs in precipitating atheromatous embolization is discussed and the importance of recognizing the syndrome is emphasized.

摘要

报告了5例因动脉粥样硬化栓塞导致“蓝色或紫色”足趾综合征的患者,可能由口服抗凝治疗诱发。其中4例症状在开始口服抗凝剂几周后出现,第5例症状因香豆素类药物明显加重。抗凝治疗前,1例患者接受过溶栓治疗疗程,2例接受过动脉插管且未发生栓塞事件。4例患者进行的诊断性动脉造影未引发新症状。所有患者均有晚期动脉粥样硬化。4例发现主动脉和/或盆腔动脉表面粗糙,第5例发现高度狭窄的股动脉病变是周围栓塞的来源。所有5例患者均中断口服抗凝剂,4例接受了血管重建手术以根除动脉粥样硬化栓子的病灶。1例术后死于多器官功能衰竭。第5例患者病情较差,无法进行主-髂动脉手术。尽管1例患者因皮肤病变发展为坏疽而需要截肢,但未再发生栓塞事件,症状消失。讨论了抗凝药物在诱发动脉粥样硬化栓塞中的可能作用,并强调了识别该综合征的重要性。

相似文献

1
Atheromatous embolization precipitated by oral anticoagulants.口服抗凝剂引发的动脉粥样硬化栓塞
Int Angiol. 1994 Sep;13(3):271-4.
2
Blue toe syndrome after initiation of low-dose oral anticoagulation.低剂量口服抗凝治疗开始后出现蓝趾综合征。
Eur J Med Res. 1998 Jun 17;3(6):278-80.
3
[Surgery of abdominal aorta with horseshoe kidney].马蹄肾腹主动脉手术
Srp Arh Celok Lek. 1997 Jan-Feb;125(1-2):36-44.
4
Oral anticoagulant therapy: a precipitating factor in the pathogenesis of cholesterol embolization?口服抗凝治疗:胆固醇栓塞发病机制中的一个促发因素?
Acta Chir Belg. 1992 Jan-Feb;92(1):33-6.
5
[Blue toe syndrome--a rare but possible complication of anticoagulant therapy].蓝趾综合征——抗凝治疗一种罕见但可能出现的并发症
Duodecim. 2011;127(11):1154-7.
6
Late onset purple toe syndrome with warfarin successfully treated with fondaparinux.华法林相关的迟发性紫趾综合征经磺达肝癸钠治疗后成功缓解。
Am J Ther. 2011 Nov;18(6):e277-9. doi: 10.1097/MJT.0b013e3181df8e0a.
7
[Atheromatous embolisms and cholesterol embolisms: medical treatment].
J Mal Vasc. 1996;21 Suppl A:97-9.
8
[Blue toe syndrome; a sign of end-arterial occlusion].
Ned Tijdschr Geneeskd. 2007 Jun 9;151(23):1261-7.
9
[Factors determining late patency of aortobifemoral bypass graft].[决定主-双股动脉旁路移植术远期通畅率的因素]
Srp Arh Celok Lek. 1997 Jan-Feb;125(1-2):24-35.
10
Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (Bypass Oral Anticoagulants or Aspirin) Study.股下静脉搭桥术后患者大出血风险:治疗后果如何?荷兰BOA(搭桥手术口服抗凝剂或阿司匹林)研究
Eur J Vasc Endovasc Surg. 2005 Aug;30(2):154-9. doi: 10.1016/j.ejvs.2005.03.005. Epub 2005 Apr 25.

引用本文的文献

1
Cholesterol embolisation after thrombolytic therapy.溶栓治疗后的胆固醇栓塞
Drug Saf. 1996 Feb;14(2):78-84. doi: 10.2165/00002018-199614020-00002.